Pacira Pharmaceuticals Share Price (NASDAQ: PCRX)

$25.05

▲

-0.14

(-0.56%)

Live

Last updated on August 20, 2025 at 11:39 PM IST

$₹

Check the interactive Pacira Pharmaceuticals Stock chart to analyse performance

Pacira Pharmaceuticals stock performance

as on August 20, 2025 at 11:39 PM IST

Today's Low:$25.00
Today's High:$25.18
$25.05
0.2%
Downside
Day's Volatility :0.71%
Upside
0.52%
52 Weeks Low:$12.61
52 Weeks High:$27.64
$25.05
49.66%
Downside
52 Weeks Volatility :54.38%
Upside
9.37%

Pacira Pharmaceuticals Stock Returns

Period	Pacira Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-3.75%	1.5%	0.0%
6 Months	-3.38%	-7.1%	0.0%
1 Year	81.14%	-11.4%	0.0%
3 Years	-56.09%	2.9%	-9.6%

Pacira Pharmaceuticals, Inc. Key Stats

Check Pacira Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$25.19
Open	$25.0
Today's High	$25.22
Today's Low	$25.0
Market Capitalization	$1.1B
Today's Volume	$651.7K
52 Week High	$27.64
52 Week Low	$12.61
Revenue TTM	$705.8M
EBITDA	$158.4M
Earnings Per Share (EPS)	$-2.75
Profit Margin	-18.06%
Quarterly Earnings Growth YOY	-0.48%
Return On Equity TTM	-15.57%

Stock Returns calculator for Pacira Pharmaceuticals Stock including INR - Dollar returns

The Pacira Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Pacira Pharmaceuticals investment value today

Current value as on today

₹1,84,234

Returns

₹84,234

(+84.23%)

Returns from Pacira Pharmaceuticals Stock

₹80,346 (+80.35%)

Dollar Returns*

₹3,889 (+3.89%)

Indian investors sentiment towards Pacira Pharmaceuticals Stock

-57%

Period: Jul 20, 2025 to Aug 19, 2025. Change in 30 Days versus previous period

Search interest for Pacira Pharmaceuticals Stock from India on INDmoney has decreased by -57% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Pacira Pharmaceuticals, Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
17.05%
Vanguard Group Inc
12.04%
D. E. Shaw & Co LP
5.02%
Renaissance Technologies Corp
4.99%
Dimensional Fund Advisors, Inc.
4.79%
State Street Corp
4.41%

Analyst Recommendation on Pacira Pharmaceuticals Stock

Rating

Trend

Buy

93%Buy

6%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Pacira Pharmaceuticals(by analysts ranked 0 to 5 stars)

Pacira Pharmaceuticals Share Price Target

What analysts predicted

Upside of 15.77%

Target:

$29.00

Current:

$25.05

Pacira Pharmaceuticals share price target is $29.00, a slight Upside of 15.77% compared to current price of $25.05 as per analysts' prediction.

Pacira Pharmaceuticals Stock Insights

Price Movement
In the last 1 year, PCRX stock has moved up by 81.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 168.92M → 181.09M (in $), with an average increase of 6.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 16.04M → -4.84M (in $), with an average decrease of 135.4% per quarter
PCRX vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 63.0% return, outperforming this stock by 119.8%

Pacira Pharmaceuticals, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$421.0M	↑ 24.83%
Net Income	$-11.0M	↑ 2238.85%
Net Profit Margin	-2.62%	↓ 2.48%

	FY20	Y/Y Change
Revenue	$420.8M	↓ 0.05%
Net Income	$145.5M	↓ 1421.01%
Net Profit Margin	34.58%	↑ 37.2%

	FY21	Y/Y Change
Revenue	$541.5M	↑ 28.68%
Net Income	$42.0M	↓ 71.15%
Net Profit Margin	7.75%	↓ 26.83%

	FY22	Y/Y Change
Revenue	$666.8M	↑ 23.14%
Net Income	$15.9M	↓ 62.1%
Net Profit Margin	2.39%	↓ 5.36%

	FY23	Y/Y Change
Revenue	$675.0M	↑ 1.22%
Net Income	$42.0M	↑ 163.72%
Net Profit Margin	6.22%	↑ 3.83%

	FY24	Y/Y Change
Revenue	$701.0M	↑ 3.85%
Net Income	$-99.6M	↓ 337.3%
Net Profit Margin	-14.2%	↓ 20.42%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$167.1M	↓ 7.79%
Net Income	$9.0M	↓ 63.9%
Net Profit Margin	5.37%	↓ 8.35%

	Q2 FY24	Q/Q Change
Revenue	$178.0M	↑ 6.53%
Net Income	$18.9M	↑ 110.34%
Net Profit Margin	10.61%	↑ 5.24%

	Q3 FY24	Q/Q Change
Revenue	$168.6M	↓ 5.31%
Net Income	$-143.5M	↓ 859.64%
Net Profit Margin	-85.11%	↓ 95.72%

	Q4 FY24	Q/Q Change
Revenue	$187.3M	↑ 11.08%
Net Income	$16.0M	↓ 111.18%
Net Profit Margin	8.57%	↑ 93.68%

	Q1 FY25	Q/Q Change
Revenue	$168.9M	↓ 9.79%
Net Income	$4.8M	↓ 70.0%
Net Profit Margin	2.85%	↓ 5.72%

	Q2 FY25	Q/Q Change
Revenue	$181.1M	↑ 7.21%
Net Income	$-4.8M	↓ 200.73%
Net Profit Margin	-2.68%	↓ 5.53%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$314.3M	↑ 25.51%

	FY20	Y/Y Change
Profit	$303.5M	↓ 3.44%

	FY21	Y/Y Change
Profit	$401.3M	↑ 32.22%

	FY22	Y/Y Change
Profit	$467.5M	↑ 16.51%

	FY23	Y/Y Change
Profit	$490.3M	↑ 4.87%

	FY24	Y/Y Change
Profit	$530.5M	↑ 8.2%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$105.4M	↓ 11.62%

	Q2 FY24	Q/Q Change
Profit	$119.4M	↑ 13.34%

	Q3 FY24	Q/Q Change
Profit	$129.7M	↑ 8.6%

	Q4 FY24	Q/Q Change
Profit	$147.4M	↑ 13.61%

	Q1 FY25	Q/Q Change
Profit	$134.6M	↓ 8.65%

	Q2 FY25	Q/Q Change
Profit	$140.2M	↑ 4.17%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$70.5M	↑ 44.3%
Investing Cash Flow	$-128.5M	↓ 724.46%
Financing Cash Flow	$3.7M	↓ 59.01%

	FY20	Y/Y Change
Operating Cash Flow	$77.0M	↑ 9.23%
Investing Cash Flow	$-277.6M	↑ 116.06%
Financing Cash Flow	$222.3M	↑ 5957.33%

	FY21	Y/Y Change
Operating Cash Flow	$125.7M	↑ 63.2%
Investing Cash Flow	$-20.8M	↓ 92.51%
Financing Cash Flow	$380.7M	↑ 71.25%

	FY22	Y/Y Change
Operating Cash Flow	$145.3M	↑ 15.56%
Investing Cash Flow	$-225.2M	↑ 983.14%
Financing Cash Flow	$-401.5M	↓ 205.47%

	FY23	Y/Y Change
Operating Cash Flow	$154.6M	↑ 6.45%
Investing Cash Flow	$77.5M	↓ 134.43%
Financing Cash Flow	$-183.0M	↓ 54.42%

	FY24	Y/Y Change
Operating Cash Flow	$189.4M	↑ 22.46%
Investing Cash Flow	$-83.3M	↓ 207.4%
Financing Cash Flow	$17.4M	↓ 109.49%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$49.1M	↑ 3.19%
Investing Cash Flow	$-15.5M	↓ 285.45%
Financing Cash Flow	$-2.8M	↑ 58.35%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$53.2M	↑ 8.42%
Investing Cash Flow	$-15.2M	↓ 2.03%
Financing Cash Flow	$25.0M	↓ 986.76%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$53.9M	↑ 1.28%
Investing Cash Flow	$-52.2M	↑ 242.84%
Financing Cash Flow	$-2.8M	↓ 111.39%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$33.1M	↓ 38.55%
Investing Cash Flow	$-368.0K	↓ 99.29%
Financing Cash Flow	$-2.0M	↓ 31.28%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$35.5M	↑ 7.02%
Investing Cash Flow	$-25.6M	↑ 6864.4%
Financing Cash Flow	$-3.0M	↑ 53.15%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$12.0M	↓ 66.12%
Investing Cash Flow	$62.2M	↓ 342.55%
Financing Cash Flow	$-57.5M	↑ 1820.67%

Pacira Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Pacira Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Pacira Pharmaceuticals, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Pacira Pharmaceuticals, Inc.	13.49%	-3.38%	81.14%	-56.09%	-58.69%
Haleon Plc Spon Ads	2.31%	-2.3%	-1.02%	56.75%	31.58%
United Therapeutics Corporation	6.99%	-17.64%	-9.59%	42.35%	76.36%
Zoetis Inc.	5.63%	-0.62%	-15.21%	-5.68%	-1.7%
Neurocrine Biosciences Inc.	0.78%	16.28%	-11.18%	25.09%	17.46%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Pacira Pharmaceuticals, Inc.	13.21	NA	-3.83	2.87	-0.16	0.03	NA	16.88
Haleon Plc Spon Ads	21.51	21.51	3.09	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	12.22	12.22	1.43	26.61	0.19	0.13	NA	158.65
Zoetis Inc.	26.84	26.84	2.47	6.32	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	39.29	39.29	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Pacira Pharmaceuticals, Inc.	Buy	$1.1B	-58.69%	13.21	-18.06%
Haleon Plc Spon Ads	Buy	$43.4B	31.58%	21.51	13.81%
United Therapeutics Corporation	Buy	$14.2B	76.36%	12.22	40.36%
Zoetis Inc.	Buy	$69.0B	-1.7%	26.84	27.83%
Neurocrine Biosciences Inc.	Buy	$13.2B	17.46%	39.29	13.88%

About Pacira Pharmaceuticals, Inc.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Organization	Pacira Pharmaceuticals
Employees	788
CEO	Mr. Frank D. Lee
Industry	Health Technology

Key Management of Pacira Pharmaceuticals, Inc.

Name	Title
Mr. Frank D. Lee	CEO & Director
Mr. Shawn M. Cross	Chief Financial Officer
Ms. Lauren Bullaro Riker	Principal Accounting Officer & Senior VP of Finance
Ms. Kristen Williams Esq., J.D.	Chief Administrative Officer & Secretary
Mr. David M. Stack	Advisor
Dr. Jonathan Slonin M.D.	Chief Medical Officer
Ms. Susan Mesco	Head of Investor Relations
Mr. Anthony Molloy III, Esq.	Chief Legal & Compliance Officer
Mr. Christopher C. Young	Chief Manufacturing Officer
Ms. Krys Corbett Esq.	Chief Business Officer

Important FAQs about investing in PCRX Stock from India :

What is Pacira Pharmaceuticals share price today?

Pacira Pharmaceuticals share price today is $25.05 as on August 20, 2025 at 11:39 PM IST. Pacira Pharmaceuticals share today touched a day high of $25.18 and a low of $25.00.

What is the 52 week high and 52 week low for Pacira Pharmaceuticals share?

Pacira Pharmaceuticals share touched a 52 week high of $27.64 and a 52 week low of $12.61. Pacira Pharmaceuticals stock price today i.e. August 20, 2025 at 11:39 PM IST is trending at $25.05, lower by 9.37% versus the 52 week high.

How to invest in Pacira Pharmaceuticals Stock (PCRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Pacira Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Pacira Pharmaceuticals Shares that will get you 0.0599 shares as per Pacira Pharmaceuticals share price of $25.05 per share as on August 20, 2025 at 11:39 PM IST.

What is the minimum amount required to buy Pacira Pharmaceuticals Stock (PCRX) from India?

Indian investors can start investing in Pacira Pharmaceuticals (PCRX) shares with as little as ₹87.0225 or $1 (as of August 20, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹870.22 in Pacira Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 20, 2025). Based on Pacira Pharmaceuticals share’s latest price of $25.05 as on August 20, 2025 at 11:39 PM IST, you will get 0.3992 shares of Pacira Pharmaceuticals. Learn more about fractional shares .

What are the returns that Pacira Pharmaceuticals has given to Indian investors in the last 5 years?

Pacira Pharmaceuticals stock has given -58.69% share price returns and 16.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?